Cargando…

Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011

AIMS AND OBJECTIVES: To study the change in the incidence and pattern of nevirapine (NVP)-induced adverse cutaneous reactions (ADR) after commencement of revised National AIDS Control Organisation (NACO) guidelines for initiation of antiretroviral therapy (ART) since Nov 2011. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokhande, Archana J, Sutaria, Amita, Shah, Bela J, Shah, Asha N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841661/
https://www.ncbi.nlm.nih.gov/pubmed/24339462
http://dx.doi.org/10.4103/2589-0557.120545
_version_ 1782292822646325248
author Lokhande, Archana J
Sutaria, Amita
Shah, Bela J
Shah, Asha N
author_facet Lokhande, Archana J
Sutaria, Amita
Shah, Bela J
Shah, Asha N
author_sort Lokhande, Archana J
collection PubMed
description AIMS AND OBJECTIVES: To study the change in the incidence and pattern of nevirapine (NVP)-induced adverse cutaneous reactions (ADR) after commencement of revised National AIDS Control Organisation (NACO) guidelines for initiation of antiretroviral therapy (ART) since Nov 2011. MATERIALS AND METHODS: The study was conducted on patients who developed cutaneous reactions after starting NVP based regimen. According to the revised NACO ART initiation guidelines Nov 2011, ART should be started if CD4 count is < 350 cells/mm(3) in stages 1, and 2 and irrespective of CD4 count in stages 3, and 4. Patients were divided in groups A and B. Group A consisted of patients enrolled on NVP-based regimen during Jan 2011 to Oct 2011, whereas, in Group B patients from Nov 2011 to Aug 2012 were included. Grading of rash, appropriate investigations and management was done. OBSERVATIONS: In Group A, out of 645 patients 30 (4.66%) patients developed cutaneous reactions, where as in Group B out of 720, 65 (9.03%) patients presented with drug reaction. In Group A (n = 30) developed reaction as Grade 1 in 1.55% (n = 10), Grade 2 in 1.86% (n = 12), grades 3 and 4 in 0.76% (n = 5) and 0.47% (n = 3), respectively. In Group B (n = 65) developed reaction, out of which Grade 1 reaction was seen in 1.39% (n = 10), Grade 2 was seen in 2.78% (n = 20), grades 3 and 4 was seen in 3.33% (n = 24) and, 1.53% (n = 11), respectively. CONCLUSION: There is a striking increase in the incidence of NVP-induced cutaneous reactions of all forms and considerable increase in frequency of severe kind of reactions with the revised guidelines.
format Online
Article
Text
id pubmed-3841661
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38416612013-12-11 Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011 Lokhande, Archana J Sutaria, Amita Shah, Bela J Shah, Asha N Indian J Sex Transm Dis AIDS Original Article AIMS AND OBJECTIVES: To study the change in the incidence and pattern of nevirapine (NVP)-induced adverse cutaneous reactions (ADR) after commencement of revised National AIDS Control Organisation (NACO) guidelines for initiation of antiretroviral therapy (ART) since Nov 2011. MATERIALS AND METHODS: The study was conducted on patients who developed cutaneous reactions after starting NVP based regimen. According to the revised NACO ART initiation guidelines Nov 2011, ART should be started if CD4 count is < 350 cells/mm(3) in stages 1, and 2 and irrespective of CD4 count in stages 3, and 4. Patients were divided in groups A and B. Group A consisted of patients enrolled on NVP-based regimen during Jan 2011 to Oct 2011, whereas, in Group B patients from Nov 2011 to Aug 2012 were included. Grading of rash, appropriate investigations and management was done. OBSERVATIONS: In Group A, out of 645 patients 30 (4.66%) patients developed cutaneous reactions, where as in Group B out of 720, 65 (9.03%) patients presented with drug reaction. In Group A (n = 30) developed reaction as Grade 1 in 1.55% (n = 10), Grade 2 in 1.86% (n = 12), grades 3 and 4 in 0.76% (n = 5) and 0.47% (n = 3), respectively. In Group B (n = 65) developed reaction, out of which Grade 1 reaction was seen in 1.39% (n = 10), Grade 2 was seen in 2.78% (n = 20), grades 3 and 4 was seen in 3.33% (n = 24) and, 1.53% (n = 11), respectively. CONCLUSION: There is a striking increase in the incidence of NVP-induced cutaneous reactions of all forms and considerable increase in frequency of severe kind of reactions with the revised guidelines. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3841661/ /pubmed/24339462 http://dx.doi.org/10.4103/2589-0557.120545 Text en Copyright: © Indian Journal of Sexually Transmitted Diseases and AIDS http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lokhande, Archana J
Sutaria, Amita
Shah, Bela J
Shah, Asha N
Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011
title Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011
title_full Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011
title_fullStr Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011
title_full_unstemmed Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011
title_short Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011
title_sort changing incidence of nevirapine-induced cutaneous drug reactions: after revised guideline nov 2011
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841661/
https://www.ncbi.nlm.nih.gov/pubmed/24339462
http://dx.doi.org/10.4103/2589-0557.120545
work_keys_str_mv AT lokhandearchanaj changingincidenceofnevirapineinducedcutaneousdrugreactionsafterrevisedguidelinenov2011
AT sutariaamita changingincidenceofnevirapineinducedcutaneousdrugreactionsafterrevisedguidelinenov2011
AT shahbelaj changingincidenceofnevirapineinducedcutaneousdrugreactionsafterrevisedguidelinenov2011
AT shahashan changingincidenceofnevirapineinducedcutaneousdrugreactionsafterrevisedguidelinenov2011